Etiket: Aşı

Vaccine Damage Scheme Costs Skyrocket Amid Rising Claims

Since April 2022, the government’s scheme to support individuals injured by Covid vaccines has seen expenses soar to a staggering £83 million. This

Since April 2022, the government’s scheme to support individuals injured by Covid vaccines has seen expenses soar to a staggering £83 million. This figure comes as new statistics reveal that over 24,000 claims have been filed, predominantly concerning the AstraZeneca jab. To put it in perspective, the amount allocated for administrative and medical assessment costs has surpassed the £32 million that has been doled out in actual support to victims, more than doubling the aid provided.

The Taxpayers’ Alliance think tank has expressed that the public will be “stunned” to learn about the disproportionate spending. Baroness Heather Hallett, chair of the group, emphasized that the administrative costs and fees for medical assessors are largely driven by the sheer volume of claims received. Since taking over the administration of the Vaccine Damage Payment Scheme (VDPS) in November 2021, there has been a noticeable uptick in claims, highlighting the inefficiency of the current system. Hallett has called for a reevaluation of the payouts, suggesting they should reflect the severity of the injuries sustained, arguing that the scheme offers “too little, too late, to too few.”

The situation has prompted scrutiny over the large sums allocated to external medical providers responsible for conducting assessments. John O’Connell, chief executive of the Taxpayers’ Alliance, pointed out that the administrative costs have ballooned to far more than what has actually been distributed to those harmed by the vaccines. He criticized the scheme for its “unnecessary bureaucracy” and stated that the Department for Health and Social Care is currently “carefully considering” recommendations for reforming the scheme, with a response expected shortly from the government.

Meanwhile, the NHS Business Services Authority (NHSBSA) has assured that it continues to collaborate closely with the government in managing the costs associated with the VDPS. As the public awaits clarity on the future of the scheme and its funding, many are left wondering about the fate of those who have suffered vaccine-related injuries. The pressing question remains: will the government take decisive steps to improve the support for victims, or will the current inefficiencies persist?

Kaynak: Orijinal Haber

New Super Flu Vaccine Rollout Kicks Off Amid NHS Challenges

This winter, the new Super-K strain is on the horizon, and the first doses of the vaccine are being administered to schoolchildren and pregnant women

This winter, the new Super-K strain is on the horizon, and the first doses of the vaccine are being administered to schoolchildren and pregnant women starting this Tuesday. Last winter, flu hit hard and early, thanks to a mutated version of the virus that made the rounds – a seasonal influenza known as subclade K or Super-K. The focus is now on schoolchildren, who are being prioritized for the jab, as they are quick to catch and spread the flu, putting at risk not just themselves but also their baby siblings and grandparents.

From October onwards, other eligible groups, including those aged 65 and over, can also receive a free NHS flu shot, with invites being sent out via phone or post. The vaccine from last season has been tweaked a bit, especially to better combat subclade K. But there’s still uncertainty about when the flu will hit this year, and whether it will be a severe season. Experts are turning their gaze towards southern hemisphere countries like Australia and New Zealand, whose flu season peaks around July or August. So far, these countries have had a relatively mild flu year, giving some hope for the UK.

Dr. Amanda Doyle from NHS England has urged caution, stating, “Last year, everyone was at risk of catching flu. It doesn’t matter how fit and healthy you are, or your age.” She reassured that the vaccine cannot give you the flu; instead, it helps your body learn how to fight the virus. Children aged two and older will receive the vaccine as a nasal spray, while adults will get an injection. Just one dose is sufficient for protection heading into the winter months.

High street pharmacies are stepping up, offering NHS flu vaccines, alongside GPs and schools. For those who don’t qualify for a free jab, the cost is about £10 to £20. Schoolchildren and pregnant women can access their free vaccines from September onwards. Starting in October, free vaccines will also be available for children two years and older who haven’t started school yet, those with certain long-term health conditions, individuals who are primary caregivers for older or disabled persons, or those receiving disability benefits.

But amidst all this, there’s a looming chaos in ADHD and autism care, and new HPV home-testing kits are rolling out for women in England who have missed cervical screenings. The NHS is clearly in a period of regrouping, grappling with multiple challenges while trying to ensure the health of the public.

Bakalım bu kış grip durumu ne olacak? Gelişmeleri takip ediyoruz…

Kaynak: Orijinal Haber

New Vaccine Breakthrough Offers Hope Against Skin Cancer Recurrence!

A new personalised vaccine, used in tandem with an existing drug, has shown promise in preventing the return of skin cancer in high-risk patients dur

A new personalised vaccine, used in tandem with an existing drug, has shown promise in preventing the return of skin cancer in high-risk patients during a clinical trial. This breakthrough, developed by Merck & Co (also known as MSD) and Moderna, targets individuals with high-risk melanoma, a particularly aggressive form of skin cancer. The vaccine was administered after patients underwent surgery, and the early results are nothing short of exciting, indicating that the jab has prolonged the period these patients remained cancer-free.

In this trial, scientists harnessed mRNA technology, the same innovative approach that powered some of the Covid-19 vaccines. By surgically excising a small portion of the patient’s tumor, they were able to tailor the vaccine to specifically address mutations present in the cancer cells. This targeted strategy instructs the immune system to identify and combat any residual tumor cells that might linger post-surgery.

Stephane Bancel, Moderna’s chief executive, expressed that these findings could signify a pivotal moment in cancer treatment, showcasing the vaccine’s potential to revolutionize how we approach melanoma and possibly other cancers. Indeed, the companies are currently exploring similar personalized vaccines for lung, bladder, and kidney cancers, further expanding the horizons of oncological therapies.

Dr. Lennard Lee, a consultant medical oncologist and associate professor at the University of Oxford, chimed in on the findings, emphasizing their importance and potential impact on patient care. He mentioned that more detailed results from the study will be unveiled at an upcoming medical conference in October, generating a buzz of anticipation in the medical community.

The excitement surrounding this development is palpable. It feels like we’re on the brink of something truly transformative in cancer treatment. As we look forward to the forthcoming conference, where more insights are expected, one can’t help but wonder: could this be the beginning of a new era in cancer therapy?

Kaynak: Orijinal Haber

First Volunteer Receives Experimental Ebola Vaccine in Oxford!

Ed Hunt, a 37-year-old man from the UK, has made headlines as the world’s first volunteer to receive an experimental vaccine against the Ebola viru

Ed Hunt, a 37-year-old man from the UK, has made headlines as the world’s first volunteer to receive an experimental vaccine against the Ebola virus, and it all went down in Oxford. The decision to step up came after Hunt was moved by the grim news reports of the Ebola outbreak in the Democratic Republic of Congo. He had initially wanted to join the Covid vaccine trials but due to work commitments, he couldn’t. But after seeing the devastation in DR Congo, he thought, “Why not do my part?”

The vaccine, developed in a remarkably short span of just eight weeks, is built on the same technology that was used for the UK’s earlier Covid vaccine. Hunt, in an interview, emphasized that this trial won’t expose anyone to the Ebola virus. Instead, the focus is on generating a robust immune response that could potentially protect against the Bundibugyo species of Ebola.

As Hunt received the shot, it wasn’t just a personal milestone; it was a moment of hope. The UK is now taking significant steps in tackling the Ebola threat with this trial. Just recently, Uganda celebrated a ‘moment of joy’ as the last Ebola patient was discharged, signaling a possible end to their outbreak.

What’s exciting here is that this vaccine trial not only aims to protect individuals but could pave the way for broader immunization strategies against this deadly virus. The world is watching closely, and the urgency couldn’t be greater, especially with the recent surge in Ebola cases globally.

So, what do you think? Will this trial mark a turning point in the fight against Ebola? Only time will tell, and we’ll be keeping a close eye on how things unfold in the coming weeks.

Kaynak: Orijinal Haber

UK Launches Urgent Trials for Rapidly Developed Ebola Vaccine

A new Ebola vaccine is set to enter human trials after being given the green light by UK regulators. Scientists from the University of Oxford kicked

A new Ebola vaccine is set to enter human trials after being given the green light by UK regulators. Scientists from the University of Oxford kicked off the development just eight weeks ago, following a public health emergency declaration on May 17. This vaccine is the first of four in development to reach this critical stage. Right now, they’re looking for volunteers, with the first doses expected to be administered to healthy adults in the UK “within weeks.”

The trial will involve 50 healthy adults aged between 18 and 55. Meanwhile, researchers are teaming up with partners in Uganda to lay the groundwork for trials in Africa, where the need for effective vaccines is crucial. Volunteers will be closely monitored for an entire year. However, scientists anticipate being able to determine relatively quickly whether the vaccine can trigger the desired immune response or if it produces any unexpected side effects.

What’s exciting is how the Oxford team managed to whip up this vaccine in such a short time – they’re utilizing the same tech that gained fame during the Covid pandemic, specifically the platform used for the Oxford/AstraZeneca Covid vaccine. This innovative approach employs a common cold virus that infects chimpanzees, which has been genetically modified to ensure it’s safe. Think of it like sending a letter in an envelope – the researchers just need to swap out the message inside before delivering it to the body. For Covid, that message was a snippet of the virus’s genetic code.

Now, the Medicines and Healthcare Products Regulatory Agency has officially approved the commencement of human trials. Vaccine researcher Alex Sampson shared with the BBC that typically, vaccines can take up to a decade to research, develop, and prove effective. However, he emphasizes that no corners are being cut, stating, “We are able to do them in parallel, so it means a lot of teams working in lots of different places around the clock, but we’re still doing everything that we would normally do.”

He also stressed the importance of safety, reminding everyone that the Covid AstraZeneca vaccine was given to millions of people without issues. In a heartfelt moment, he reflected on his personal loss, saying, “I buried my parents one day after the other.”

The urgency behind this trial is palpable, and one can’t help but wonder how quickly we might see results. Will this vaccine be able to fend off the deadly Ebola virus effectively? Only time will tell…

Kaynak: Orijinal Haber

Revolutionary AI-Designed Vaccine Could Change Pandemic Preparedness Forever!

Researchers at the University of Cambridge have made a groundbreaking announcement: they’ve developed a vaccine designed entirely by artificial in

Researchers at the University of Cambridge have made a groundbreaking announcement: they’ve developed a vaccine designed entirely by artificial intelligence, and it’s being hailed as a “fundamentally new” type of vaccine. This innovative jab could potentially protect against a wide range of viruses, making it a crucial tool in preventing future pandemics. The excitement in the air is palpable as this is the first time that a vaccine’s key component has been fully crafted through AI technology and subsequently trialed in humans.

So, what makes this vaccine so special? Well, it’s engineered to combat all coronaviruses, which means it covers every variant of Covid we’ve seen so far, plus those pesky viruses that currently jump between animals and humans and could spark the next global health crisis. Hold on to your hats, folks, because while this research is still in its infancy, the Cambridge team is already working on separate vaccines targeting flu and Ebola too.

Vaccines, as we know, teach our bodies to recognize and fend off infections. But here’s the kicker: some viruses are masters at changing their appearance, like chameleons, which means our vaccines can quickly become outdated. This is exactly why we need to regularly update Covid and winter flu vaccines. As Prof. Jonathan Heeney from the University of Cambridge puts it, “We’re always behind.” But now, they’re aiming to get ahead of the curve – so far ahead that they might even protect us from new outbreaks or pandemics before they arise.

Traditionally, vaccine development relies on existing strains of viruses, but the clever folks at Cambridge took a different route. They analyzed genetic codes from various coronaviruses, collected through surveillance programs that monitor potential viral threats. These codes were then fed into an AI system, which created a “super-antigen.” This isn’t just any antigen; it’s designed to train our immune systems to recognize and attack the entire family of coronaviruses, even those that might mutate or jump from animals to humans. How cool is that? Antigens are the heart of vaccines, the very elements our immune systems learn to target.

Prof. Heeney emphasizes that this is the first instance of an AI-designed antigen being trialed on humans, and the results are nothing short of astonishing. He noted, “This technology is surprising all of us,” adding that it’s “amazing what we can do with it for the good of humanity.” He further explained that these vaccines aim to shield us not just from today’s viruses but from future outbreaks and diseases. This approach represents a significant shift in how we prepare for pandemics.

The initial trials involved 39 participants, primarily focused on assessing the safety of this new vaccine. A more extensive second study, which will include around 200 individuals, aims to provide deeper insights into how effectively this vaccine trains the immune system. The results published in the Journal of Infection indicate that the immune response generated was “modest,” but the excitement surrounding these early findings is undeniable.

Prof. Saul Faust, who conducted some of the trials at the University of Southampton, expressed optimism about the AI design. He stated that it “definitely has potential” and remarked on its capacity to adapt to the ever-changing landscape of potential pandemics. The Cambridge team isn’t stopping here; they’re already conducting animal research on universal seasonal flu vaccines that wouldn’t require yearly tweaks, along with an H5N1 bird flu vaccine, just in case the current crisis affecting birds turns into a human pandemic. And let’s not forget about viral hemorrhagic fevers, including Ebola, especially with the ongoing outbreak in the Democratic Republic of Congo, which involves a strain lacking a developed vaccine.

Prof. Andy Pollard, director of the Oxford Vaccine Group and not directly involved in the study, shared that this innovative approach is generating compelling evidence in animal research. He called the data “fascinating,” noting that such immune responses were unexpected. However, he cautioned that the real test lies ahead in human trials, given the differences between our immune systems and those of laboratory mice, which have been shaped by years of infections.

Looking ahead, the role of artificial intelligence in vaccine research is poised to be a “game changer.” AI tools have the potential to predict how our immune systems will respond to vaccines, significantly speeding up the development process and ultimately saving lives. Prof. Marian Knight, scientific director for the National Institute for Health and Care Research, highlighted that the success of this AI-designed “super-antigen” trial marks a pivotal leap forward in providing broad, lasting viral protection.

Science Minister Lord Vallance chimed in, celebrating yet another British scientific success story. He pointed out that this is a prime example of how our research expertise, combined with AI, can lead to new treatment options. With the first human trials showing promising results, this could indeed expedite vaccine rollouts, benefitting people globally in the long term. So, what’s next for this revolutionary vaccine? We’ll be keeping a keen eye on future developments…

Kaynak: Orijinal Haber

Australia Faces Diphtheria Crisis: First Death in Nearly a Decade

Australia has reported its first diphtheria death in almost ten years as the country battles its worst outbreak of this vaccine-preventable illness i

Australia has reported its first diphtheria death in almost ten years as the country battles its worst outbreak of this vaccine-preventable illness in decades. The Northern Territory (NT) declared a diphtheria outbreak in March, with cases also surfacing in Western Australia, South Australia, and Queensland. The spike in cases began in late 2025, escalating sharply in February, and this year alone has seen 245 confirmed cases, marking the largest outbreak since 1991, predominantly affecting remote Indigenous communities.

On Tuesday, the health minister of NT announced that autopsy results from an overseas laboratory confirmed diphtheria as the cause of a man’s death in April at Royal Darwin Hospital. This tragic event marks the first diphtheria-related death since 2018. Yahu, it’s alarming, isn’t it? The government has stepped up vaccination efforts in high-risk areas, and, according to health officials, the number of new cases is now beginning to decline. “Our government has taken this situation very seriously, and we are working hard to understand the causes and contain the situation,” NT Health Minister Steve Edgington stated.

Since March 30, the vaccination campaign has already delivered 10,407 doses. Between January last year and May this year, the NT recorded 163 cases of diphtheria, with 48 being respiratory cases and 115 cutaneous cases that spread through skin contact. Can you believe that in March, health officials in Western Australia confirmed two respiratory diphtheria cases? This was the first time in over 50 years that such cases were reported there.

A staggering 60% of this year’s cases are from the Northern Territory, followed by Western Australia with about 36%. There are a handful of cases in South Australia and even fewer in Queensland. The authorities are urging those in affected communities to get their vaccinations updated, particularly teenagers and adults who need booster shots.

Pop-up clinics have been established across Darwin, Katherine, and Alice Springs to raise awareness about the vaccination campaign. Health officials emphasize that vaccines are the “most important measure for preventing, protecting, and reducing transmission.” Both strains of diphtheria, respiratory and cutaneous, can be prevented through vaccination, which typically involves five doses given to children between two months and four years, followed by a booster shot between the ages of 12 and 13.

Respiratory diphtheria usually starts with fever or chills and a sore throat, leading to serious breathing and swallowing difficulties. On the other hand, cutaneous diphtheria presents as infected sores or ulcers on exposed body parts, which heal slowly but rarely lead to severe illness. It’s understood that the last reported diphtheria death before this was in 2018, as reported by ABC.

Just last week, Australia’s Chief Medical Officer, Prof. Michael Kidd, declared diphtheria a communicable disease incident of national significance. In response to the outbreak, the government announced a AU$7.2 million package dedicated to enhancing vaccination efforts and resources in affected areas.

Bakalım, bundan sonra ne olacak? Gelişmeleri hep birlikte takip ediyoruz…

Kaynak: Orijinal Haber

UK Scientists Race Against Time to Develop Ebola Vaccine Amid Outbreak

Scientists at Oxford University are in a race against time, working on a new Ebola vaccine that could be ready for clinical trials in just two to thr

Scientists at Oxford University are in a race against time, working on a new Ebola vaccine that could be ready for clinical trials in just two to three months. This urgent effort comes as the outbreak in the Democratic Republic of Congo has escalated alarmingly, with 750 suspected cases and 177 deaths reported. The strain of Ebola they’re targeting, known as Bundibugyo, is particularly deadly, killing approximately one-third of those it infects and, crucially, there’s currently no proven vaccine for it.

Now, the situation is looking quite serious. The World Health Organization (WHO) has raised the risk level from “high” to “very high” in the affected areas of Congo, and while the broader region also faces a high risk, globally the threat remains low. This escalation follows the WHO’s declaration of a public health emergency of international concern, emphasizing that this outbreak is not yet a pandemic.

Interestingly, another experimental vaccine for Bundibugyo is being developed, but it may take six to nine months before it’s ready for testing. The vaccine being crafted by the Oxford team employs the same technology they used during the Covid pandemic. This adaptable technology, referred to as ChAdOx1, can be quickly modified to combat different infections. Previously, it was infused with genetic material from the Covid virus, but now it’s been re-engineered using genetic information from the Bundibugyo strain of Ebola.

This innovative vaccine uses a common cold virus that usually infects chimpanzees, but it’s been modified to ensure safety for humans. By utilizing this altered cold virus, researchers can deliver critical genetic material about the Bundibugyo virus to human cells, effectively training the immune system to recognize and combat the actual disease without causing any infection or Ebola symptoms.

However, there’s a catch. The WHO has pointed out that there isn’t any animal data yet to bolster the effectiveness of this specific vaccine. A spokesperson mentioned, “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty.” The effectiveness will hinge on the results of ongoing animal trials, which are reportedly underway in Oxford.

Once the vaccine is ready for mass production, the Serum Institute of India is set to step in and help produce it on a large scale, pending the delivery of medical-grade materials from Oxford. Professor Lambe, who heads the Vaccine Immunology department at the Oxford Vaccine Group, emphasized the need for speed, stating, “Once we get starting material to them they can go fast and they can go big.”

As for the current outbreak, it’s proving to be quite challenging due to the rarity of the Bundibugyo strain. Among the six species of the Ebola virus, only three are known to cause significant outbreaks. Bundibugyo has a limited history, with just two previous outbreaks documented—one in Uganda in 2007 and another in DR Congo in 2012. In fact, it hasn’t been seen for over a decade. While vaccines are available for the more common Zaire strain, the Bundibugyo strain remains without a proven vaccine.

It’s important to note that, unlike the mass vaccination efforts during the Covid pandemic, Ebola vaccines will be administered using a method called ring vaccination. This means only those individuals who are most at risk, including close contacts of Ebola cases and healthcare workers treating infected patients, will be immunized.

The Oxford team has been diligently working on similar vaccines for other strains of Ebola and even the Marburg virus. They might have caught this rare strain before the outbreak was officially recognized, according to reports from the Red Cross.

As the race continues to develop this critical vaccine, one can’t help but wonder how effective it will be and what the next steps will be if this outbreak escalates further. The world watches closely…

Kaynak: Orijinal Haber